Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer

Expert Opinion on Investigational Drugs

Volumn 24, Issue 6, 2015, Pages 809-824

  Santoni, Matteo ^a   Massari, Francesco ^b   Del Re, Marzia ^c   Ciccarese, Chiara ^b   Piva, Francesco ^a   Principato, Giovanni ^a   Montironi, Rodolfo ^a   Santini, Daniele ^d   Danesi, Romano ^c   Tortora, Giampaolo ^b   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Cancer; Clinical trial; Signal transducer and activator of transcription 3; Tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 9150; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JANUS KINASE 2 INHIBITOR; MICRORNA; NATURAL PRODUCT; OPB 31121; OPB 51602; SPHINGOSINE 1 PHOSPHATE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG TARGETING; ESOPHAGUS CANCER; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; ANIMAL; DRUG DESIGN; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; STAT3 TRANSCRIPTION FACTOR;

EID: 84929321217     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1020370     Document Type: Review

References (141)

1. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21
2. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105
3. Raz R, Durbin JE, Levy DE. Acute phase response factor and additional members of the interferon-stimulated gene factor 3 family integrate diverse signals from cytokines, interferons, and growth factors. J Biol Chem 1994;269:24391-5
4. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303
5. Ng IH, Bogoyevitch MA, Jans DA. Cytokine-induced slowing of STAT3 nuclear import; faster basal trafficking of the STAT3β isoform. Traffic 2014;15:946-60
6. Zammarchi F, de Stanchina E, Bournazou E, et al. Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci USA 2011;108:17779-84
7. Ng IH, Ng DC, Jans DA, Bogoyevitch MA. Selective STAT3-α or -βb expression reveals spliceform-specific phosphorylation kinetics, nuclear retention and distinct gene expression outcomes. Biochem J 2012;447:125-36
8. Garcia R, Yu CL, Hudnall A, et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997;8:1267-76
9. Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptormediated cell growth in vitro. J Clin Invest 1998;102:1385-92
10. Cattaneo E, Magrassi L, De-Fraja C, et al. Variations in the levels of the JAK/STAT and ShcA proteins in human brain tumors. Anticancer Res 1998;18:2381-7
11. Flørenes VA, Lu C, Bhattacharya N, et al. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene 1999;18:1023-32
12. Kirkwood JM, Farkas DL, Chakraborty A, et al. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med 1999;5:11-20
13. Lou W, Ni Z, Dyer K, et al. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 2000;42:239-42
14. Magrassi L, De-Fraja C, Conti L, et al. Expression of the JAK and STAT superfamilies in human meningiomas. J Neurosurg 1999;91:440-6
15. Pansky A, Hildebrand P, Fasler-Kan E, et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 2000;85:720-5
16. Schrell UM, Koch HU, Marschalek R, et al. Formation of autocrine loops in human cerebral meningioma tissue by leukemia inhibitor factor, interleukin-6, and oncostatin M: inhibition of meningioma cell growth in vitro by recombinant oncostatin M. J Neurosurg 1998;88:541-8
17. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol 1999;11:490-6
18. Coffer PJ, Koenderman L, de Groot RP. The role of STATs in myeloid differentiation and leukemia. Oncogene 2000;19:2511-22
19. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 1997;100:3140-8
20. Gouilleux-Gruart V, Gouilleux F, Desaint C, et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996;87:1692-7
21. Weber-Nordt RM, Egen C, Wehinger J, et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 1996;88:809-16
22. Zhang Q, Nowak I, Vonderheid EC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996;93:9148-53
23. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009;18:45-56
24. Silva CM. Role of STATs as downstream signal transducers in Src family kinasemediated tumorigenesis. Oncogene 2004;23:8017-23
25. Vinkemeier U. Getting the message across, STAT! Design principles of a molecular signaling circuit. J Cell Biol 2004;167:197-201
26. Gorlich D. Transport into and out of the cell nucleus. Embo J 1998;17:2721-7
27. Ma J, Zhang T, Novotny-Diermayr V, et al. A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation. J Biol Chem 2003;278:29252-60
28. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007;251:199-210
29. Braunstein J, Brutsaert S, Olson R, Schindler C. STATs dimerize in the absence of phosphorylation. J Biol Chem 2003;278:34133
30. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95-8
31. West NR, Murray JI, Watson PH. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene 2014;33:1485-94
32. Guo L, Chen C, Shi M, et al. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelia lmesenchymal transition. Oncogene 2013;32:5272-82
33. Wen Z, Zhong Z, Darnell JE. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-50
34. Chung J, Uchida E, Grammer TC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997;17:6508-16
35. Bhattacharya S, Schindler C. Regulation of Stat3 nuclear export. J Clin Invest 2003;111:553-9
36. Wendt MK, Balanis N, Carlin CR, Schiemann WP. STAT3 and epithelialmesenchymal transitions in carcinomas. JAKSTAT 2014;3:e28975
37. Morita Y, Naka T, Kawazoe Y, et al. Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts. Proc Natl Acad Sci USA 2000;97:5405-10
38. Kramer OH, Baus D, Knauer SK, et al. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev 2006;20:473-85
39. Kramer OH, Knauer SK, Greiner G, et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev 2009;23:223-35
40. Nie Y, Erion DM, Yuan Z, et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol 2009;11:492-500
41. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-21
42. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996;84:443-50
43. Meraz MA, White JM, Sheehan KC, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996;84:431-42
44. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008;28:477-87
45. Damsker JM, Hansen AM, Caspi RR, et al. Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci 2010;1183:211-21
46. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 2009;31:539-50
47. Hedrich CM, Rauen T, Apostolidis SA, et al. Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. Proc Natl Acad Sci USA 2014;111:13457-62
48. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-56
49. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16
50. Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007;117:3846-56
51. Concha-Benavente F, Srivastava RM, Ferrone S, Ferris RL. EGFR-mediated tumor immunoescape: the imbalance between phosphorylated STAT1 and phosphorylated STAT3. Oncoimmunology 2013;2:e27215
52. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012;36:503-14
53. Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 2012;12:121-32
54. Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009;15:283-93
55. Theiss AL. Sphingosine-1-phosphate: Driver of NFκB and STAT3 persistent activation in chronic intestinal inflammation and colitis-associated cancer. JAKSTAT 2013;2:e24150
56. Lee H, Deng J, Kujawski M, et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010;16:1421-8
57. Liang J, Nagahashi M, Kim EY, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis associated cancer. Cancer Cell 2013;23:107-20
58. Cao Q, Li YY, He WF, et al. Interplay between microRNAs and the STAT3 signaling pathway in human cancers. Physiol Genomics 2013;45:1206-14
59. Xiang M, Birkbak NJ, Vafaizadeh V, et al. STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal 2014;7:ra11
60. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15
61. Kujawski M, Kortylewski M, Lee H, et al. Stat3 mediates myeloid celldependent tumor angiogenesis in mice. J Clin Invest 2008;118:3367-77
62. Burke WM, Jin X, Lin HJ, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001;20:7925-34
63. Chiu HC, Chou DL, Huang CT, et al. Suppression of STAT3 activity sensitizes gefitinib-resistant non small cell lung cancer cells. Biochem Pharmacol 2011;81:1263-70
64. Suetsugu S, Takenawa T. Regulation of cortical actin networks in cell migration. Int Rev Cytol 2003;229:245-86
65. Teng Y, Ross JL, Cowell JK. The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. JAKSTAT 2014;3(1):e28086
66. Sun B, Kawahara M, Ehata S, Nagamune T. AAG8 promotes carcinogenesis by activating STAT3. Cell Signal 2014;26:1863-9
67. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014;16:488-94
68. Looyenga BD, Hutchings D, Cherni I, et al. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One 2012;7:e30820
69. Jiang R, Jin Z, Liu Z, et al. Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. Mol Diagn Ther 2011;15:347-52
70. Zhou J, Qu Z, Yan S, et al. Differential roles of STAT3 in the initiation and growth of lung cancer. Oncogene 2014; doi:10.1038/onc.2014.318
71. Liu RY, Zeng Y, Lei Z, et al. JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells. Int J Oncol 2014;44:1643-51
72. Xu YH, Lu S. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer. Eur J Surg Oncol 2014;40:311-17
73. Kulesza DW, Carre T, Chouaib S, Kaminska B. Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFalpha- and NK cytotoxicity. Exp Cell Res 2013;319:506-16
74. Kim SM, Kwon OJ, Hong YK, et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther 2012;11:2254-64
75. Jin HO, Lee YH, Park JA, et al. Blockage of STAT3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition. Biochem Biophys Res Commun 2014;444:502-8
76. Chung SS, Aroh C, Vadgama JV. Constitutive activation of STAT3 signaling regulates hTERT and promotes stem cell-like traits in human breast cancer cells. PLoS ONE 2013;8:e83971
77. Zhao D, Pan C, Sun J, et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene 2014; doi:10.1038/onc.2014.257
78. Li G, Zhao L, Li W, et al. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget 2014;5:8317-29
79. Yang L, Han S, Sun Y. An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelialmesenchymal transition and cancer stem cell expansion in human breast cancer cells. Biochem Biophys Res Commun 2014;453(3):582-7
80. Hassan S, Buchanan M, Jahan K, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 2011;129:225-32
81. Liu X, Xiao Q, Bai X, et al. Activation of STAT3 is involved in malignancy mediated by CXCL12-CXCR4 signaling in human breast cancer. Oncol Rep 2014;32:2760-8
82. Klampfer L. The role of signal transducers and activators of transcription in colon cancer. Front Biosci 2008;13:2888-99
83. Nguyen AV, Wu YY, Liu Q, et al. STAT3 in epithelial cells regulates inflammation and tumor progression to malignant state in colon. Neoplasia 2013;15:998-1008
84. De Simone V, Franzè E, Ronchetti G, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-κB to promote colorectal cancer cell growth. Oncogene 2014; doi:10.1038/onc.2014.286
85. Liu S, Sun X, Wang M, et al. A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells. Gastroenterology 2014;147(4):847-59.e11
86. Wan S, Zhao E, Kryczek I, et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 2014;147(6):1393-404
87. Zhu Q, Zhang X, Zhang L, et al. The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. Cell Death Dis 2014;5:e1295
88. Katsha A, Soutto M, Sehdev V, et al. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology 2013;145:1312-22.e1-8
89. Katsha A, Arras J, Soutto M, et al. AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers. Mol Oncol 2014;8(8):1419-28
90. Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67:9518-27
91. Panni RZ, Sanford DE, Belt BA, et al. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunol Immunother 2014;63:513-28
92. Wen W, Liang W, Wu J, et al. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther 2014;13(12):3037-48
93. Abubaker K, Luwor RB, Zhu H, et al. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer 2014;14:317
94. Rosen DG, Mercado-Uribe I, Yang G, et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 2006;107:2730-40
95. Puiffe ML, Le Page C, Filali-Mouhim A, et al. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 2007;9:820-9
96. Bishop JL, Thaper D, Zoubeidi A. The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel) 2014;6:829-59
97. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33
98. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97
99. Liu C, Zhu Y, Lou W, et al. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate 2014;74:201-9
100. Santoni M, Massari F, Amantini C, et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer ImmImmunother 2013;62:1757-68
101. Horiguchi A, Oya M, Marumo K, Murai M. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int 2002;61:926-38
102. Kim JE, Patel M, Ruzevick J, et al. STAT3 Activation in Glioblastoma: biochemical and Therapeutic Implications. Cancers (Basel) 2014;6:376-95
103. Nabissi M, Morelli MB, Amantini C, et al. TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. Carcinogenesis 2010;31:794-803
104. Morelli MB, Nabissi M, Amantini C, et al. The Transient receptor vanilloid-2 (TRPV2) cation channel impairs glioblastoma stem cell proliferation and promotes differentiation. Int J Cancer 2012;131:E1067-77
105. Nabissi M, Morelli MB, Santoni M, Santoni G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 2013;34:48-57
106. Liu M, Inoue K, Leng T, et al. TRPM7 channels regulate glioma stem cell through STAT3 and Notch signaling pathways. Cell Signal 2014;26:2773-81
107. Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001;276:45443-55
108. Bennnett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotised as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010;50:259-93
109. Hong DS, Younes A, Fayad LH, et al. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-inclass, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. J Clin Oncol 2013;31(Suppl):abstract 8523
110. Hayakawa F, Sugimoto K, Harada Y, et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J 2013;3:e166
111. Kim MJ, Nam HJ, Kim HP, et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett 2013;335:145-52
112. Bendell JC, Hong DS, Burris HA III, et al. Phase 1, open-label, doseescalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol 2014;74:125-30
113. Ikeda M, Okusaka T, Ishii H, et al. A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2014;32(5s Suppl):abstract 2616
114. Brambilla L, Genini D, Laurini E, et al. Novel small molecule inhibitors of signal transducer and activator of transcription (STAT3) for cancer treatment. Mol Cancer Ther 2013;12(11 Suppl):abstract nr C180
115. Genini D, Brambilla L, Laurini E, et al. Novel inhibitors of signal trasducer and activator of transcription 3 (STAT3) show potent activity in cell cultures and tumor xenografts [abstract nr 953]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research: 2014 AACR; San Diego, CA; April 5-9; 2014
116. Goh BC, Wong ALA, Soo RA, et al. Phase I study of OPB51602, a small molecule inhibitor of STAT3 phosphorylation, in patients with refractory solid malignancies. J Clin Oncol 2012;30(Suppl):abstract 3002
117. Blaskovich MA, Sun J, Cantor A, et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63:1270-9
118. Sun J, Blaskovich MA, Jove R, et al. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005;24:3236-45
119. Zhang X, Blaskovich MA, Forinash KD, Sebti SM. Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. Br J Cancer 2014;111:894-902
120. Tam CS, Verstovsek S. Investigational Janus kinase inhibitors. Expert Opin Investig Drugs 2013;22:687-99
121. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98
122. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807
123. Pardanani AD, Caramazza D, George G, et al. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. ASCO Meeting Abstracts 2011;29(15 Suppl):6514
124. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16:487-97
125. Plimack ER, Lorusso PM, McCoon P, et al. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist 2013;18:819-12
126. Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta 2014;1845:136-54
127. Erlund I. Review of the flavonoids quercetin, hesperetin, and naringenin: dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res 2004;24:851-74
128. Hollman PCH, van Trijp JMP, Mengelers MJB, et al. Bioavailability of the dietary antioxidant flavonol quercetin in man. Cancer Lett 1997;114:139-40
129. Kelly GS. Quercetin. Altern Med Rev 2011;16:172-94
130. Cao HH, Tse AKW, Kwan HY, et al. Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol 2014;87:424-34
131. Rosner K, Röpke C, Pless V, Skovgaard GL. Late type apoptosis and apoptosis free lethal effect of quercetin in human melanoma. Biosci Biotechnol Biochem 2006;70:2169-77
132. Lui GY, Kovacevic Z, Menezes S, et al. Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: inhibition of constitutive and interleukin 6 (IL6)-induced activation by iron depletion. Mol Pharmacol 2015;87(3):543-60
133. Li X, Yu Z, Li Y, et al. The tumor suppressor miR-124 inhibits cell proliferation by targeting STAT3 and functions as a prognostic marker for postoperative NSCLC patients. Int J Oncol 2015;46:798-808
134. Lee DH, Sung KS, Bartlett DL, et al. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the in colorectal cancer cells. Cell Signal 2015;27:293-305
135. Souissi I, Ladam P, Cognet JA, et al. A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line. Mol Cancer 2012;11:12
136. Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014;14:736-46
137. Suh Y, Jo S, Lee H, Lee C. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells. Int J Oncol 2014;46(3):1405-11
138. Tan FH, Putoczki TL, Stylli SS, Luwor RB. The Role of STAT3 signaling in mediating tumor resistance to cancer therapy. Curr Drug Targets 2014;15:1341-53
139. Lee HJ, Zhuang G, Cao Y, et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014;26:207-21
140. Li G, Zhao L, Li W, et al. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget 2014;5:8317-29
141. Su JC, Tseng PH, Wu SH, et al. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. Neoplasia 2014;16:595-605